GSK and Amgen - Top 5 Emerging Market Deals

Who: GlaxoSmithKline
With: Amgen
Where: China, Brazil and India

Deal Size: $120 million

Details: A year before Amgen won approval of denosumab for postmenopausal women with osteoporosis, GlaxoSmithKline snagged marketing rights for the drug in China, Brazil and India--three of the largest emerging pharmaceutical markets. Additionally, GSK got rights to sell the drug in South Korea and all other markets where Amgen doesn't have a commercial presence.

Amgen and GSK also agreed to share commercialization of denosumab in Europe, Australia, New Zealand and Mexico. The Big Biotech got an initial payment and near-term commercial milestones to Amgen totaling $120 million, and ongoing royalties. Analysts estimate the drug could eventually reach up to $2 billion in annual sales.

GSK and Amgen - Top 5 Emerging Market Deals
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.